Canopy Growth Corp CGC
Medicinal Chemicals and Botanical Products · data as of November 13, 2026
Canopy Growth Corp (CGC) is a healthcare company listed in the US with a market value of about $238M. In the twelve months to September 30, 2026 it had revenue of $216M and net income of -$188M, a net margin of -87.0%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -14% a year, a 5-year average ROIC of -37%.
About Canopy Growth
Canopy Growth is listed in the US and classified in medicinal chemicals and botanical products. Revenue went from $10M in 2019 to $204M in 2026, growth of about 54.3% a year. It was profitable in 0 of the last 8 years in our data. It spends 1% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Profit margin improving
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $216M | $204M | $187M | $219M | $246M | $380M | $434M | $280M | $10M |
| Net income | -$188M | -$189M | -$354M | -$511M | -$2.4B | -$248M | -$1.4B | -$927M | -$20M |
| Free cash flow | -$57M | -$50M | -$123M | -$210M | -$418M | -$465M | -$500M | -$1.0B | — |
| EPS (diluted) | $-0.48 | $-0.45 | $-0.84 | $-1.21 | $-5.71 | $-0.58 | $-3.27 | $-2.19 | $-0.05 |
| Net margin | -87.0% | -92.4% | -189.2% | -233.4% | -983.7% | -65.2% | -319.2% | -331.3% | -206.0% |
| ROIC | — | -13.2% | -11.5% | -17.5% | -124.1% | -19.1% | -24.0% | -28.2% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Canopy Growth pay a dividend?
Not currently.
Is Canopy Growth a good stock to buy?
We do not give buy or sell advice. Canopy Growth scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.